Research brief · 2026-09-09
Phase 1, 2, 3: What Trial Phases Mean
When a headline says a peptide 'passed a phase 2 trial', the phase number carries most of the meaning. The FDA's drug development pages describe the phases plainly.
Phase 1 is the first time a drug is given to people. The FDA describes it as typically 20 to 100 participants, often healthy volunteers, over several months. The questions are safety, tolerability and how the body absorbs and clears the drug. Whether it treats anything is not yet on the table. Phase 2 enrolls up to several hundred people who actually have the condition, over several months to two years. Now researchers look for a signal of benefit and a clearer picture of side effects, but the studies are usually too small to be definitive.
Phase 3 is where approval decisions are made. The FDA describes 300 to 3,000 participants over one to four years, usually randomized and compared against a placebo or an existing treatment. These trials are designed to show effectiveness and to catch adverse reactions that smaller studies miss. Phase 4 comes after approval, tracking thousands of patients in real use for rarer or longer-term problems. The ICH E8 guideline used by regulators worldwide describes the same progression from human pharmacology through exploratory to confirmatory studies.
The attrition is steep. According to the FDA's figures, about 70 percent of drugs move past phase 1, about 33 percent past phase 2, and roughly 25 to 30 percent past phase 3. That is why an exciting phase 2 result is best read as a hypothesis worth testing, not as evidence a treatment works.
The limit is that phase labels describe design and scale, not quality. A large phase 3 can still be badly designed, and a small phase 2 can be well run. For any actual treatment decision, the phase of the evidence is one input for a physician to weigh, not a verdict.
Sources
- U.S. Food and Drug Administration, The Drug Development Process, Step 3: Clinical Research
- FDA.gov 2018
- International Council for Harmonisation, ICH E8(R1) General Considerations for Clinical Studies
- ICH 2021
- National Institutes of Health, NIH Clinical Research Trials and You: The Basics
- NIH.gov 2022
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.